Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells

Tadashi Komata, Barbara P. Barna, Isabelle M. Germano, Satoru Kyo, Satoshi Hirohata, Yasuko Kondo, Takao Kanzawa, Hideaki Ito, Satoshi Hirohata, Shoji Koga, Hideaki Sumiyoshi, Masahiro Takakura, Masaki Inoue

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Telomerase is a distinctive candidate for targeted gene therapy of malignant gliomas, because the vast majority of malignant gliomas express telomerase activity while normal brain tissues do not. Recently, we developed a telomerase-specific expression system of caspase-8 gene using the promoter of the human telomerase reverse transcriptase (hTERT) gene. However, the transcriptional activity of hTERT-181 promoter (a 181-base pair [bp] region upstream of the transcription start site) was relatively lower in malignant glioma cells than in other tumors such as prostate cancer cells. To establish the hTERT/caspase-8 construct as a novel therapy for malignant gliomas, we need to increase the transcriptional activity of the hTERT promoter in malignant glioma cells. In the present study, we demonstrate that the transcriptional activity of hTERT-378 promoter (a 378-bp region) was 2- to 40-fold higher in hTERT-positive malignant glioma cells (A172, GB-1, T98G, U87-MG, U251-MG, and U373-MG) than that of hTERT-181. We further demonstrate that by using the hTERT-378/caspase-8 construct, apoptosis was restricted to malignant glioma cells, and was not seen in astrocytes or fibroblasts lacking hTERT. Moreover, the growth of subcutaneously established U373-MG tumors in mice was significantly inhibited by seven daily intratumoral injections of hTERT-378/caspase-8 construct and its inhibitory effect persisted during 3 additional weeks without additional treatment. These results suggest that the telomerase-specific expression of caspase-8 under hTERT-378 promoter is a novel targeting approach for the treatment of telomerase-positive malignant gliomas.

Original languageEnglish
Pages (from-to)1015-1025
Number of pages11
JournalHuman Gene Therapy
Volume13
Issue number9
DOIs
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Caspase 8
Glioma
Genetic Therapy
Telomerase
Base Pairing
human TERT protein
Transcription Initiation Site
Astrocytes
Genes
Neoplasms
Prostatic Neoplasms
Therapeutics
Fibroblasts
Apoptosis

ASJC Scopus subject areas

  • Genetics

Cite this

Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. / Komata, Tadashi; Barna, Barbara P.; Germano, Isabelle M.; Kyo, Satoru; Hirohata, Satoshi; Kondo, Yasuko; Kanzawa, Takao; Ito, Hideaki; Hirohata, Satoshi; Koga, Shoji; Sumiyoshi, Hideaki; Takakura, Masahiro; Inoue, Masaki.

In: Human Gene Therapy, Vol. 13, No. 9, 2002, p. 1015-1025.

Research output: Contribution to journalArticle

Komata, T, Barna, BP, Germano, IM, Kyo, S, Hirohata, S, Kondo, Y, Kanzawa, T, Ito, H, Hirohata, S, Koga, S, Sumiyoshi, H, Takakura, M & Inoue, M 2002, 'Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells', Human Gene Therapy, vol. 13, no. 9, pp. 1015-1025. https://doi.org/10.1089/104303402753812421
Komata, Tadashi ; Barna, Barbara P. ; Germano, Isabelle M. ; Kyo, Satoru ; Hirohata, Satoshi ; Kondo, Yasuko ; Kanzawa, Takao ; Ito, Hideaki ; Hirohata, Satoshi ; Koga, Shoji ; Sumiyoshi, Hideaki ; Takakura, Masahiro ; Inoue, Masaki. / Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. In: Human Gene Therapy. 2002 ; Vol. 13, No. 9. pp. 1015-1025.
@article{ddcc268526854d6c9ec3d99260ff2e5a,
title = "Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells",
abstract = "Telomerase is a distinctive candidate for targeted gene therapy of malignant gliomas, because the vast majority of malignant gliomas express telomerase activity while normal brain tissues do not. Recently, we developed a telomerase-specific expression system of caspase-8 gene using the promoter of the human telomerase reverse transcriptase (hTERT) gene. However, the transcriptional activity of hTERT-181 promoter (a 181-base pair [bp] region upstream of the transcription start site) was relatively lower in malignant glioma cells than in other tumors such as prostate cancer cells. To establish the hTERT/caspase-8 construct as a novel therapy for malignant gliomas, we need to increase the transcriptional activity of the hTERT promoter in malignant glioma cells. In the present study, we demonstrate that the transcriptional activity of hTERT-378 promoter (a 378-bp region) was 2- to 40-fold higher in hTERT-positive malignant glioma cells (A172, GB-1, T98G, U87-MG, U251-MG, and U373-MG) than that of hTERT-181. We further demonstrate that by using the hTERT-378/caspase-8 construct, apoptosis was restricted to malignant glioma cells, and was not seen in astrocytes or fibroblasts lacking hTERT. Moreover, the growth of subcutaneously established U373-MG tumors in mice was significantly inhibited by seven daily intratumoral injections of hTERT-378/caspase-8 construct and its inhibitory effect persisted during 3 additional weeks without additional treatment. These results suggest that the telomerase-specific expression of caspase-8 under hTERT-378 promoter is a novel targeting approach for the treatment of telomerase-positive malignant gliomas.",
author = "Tadashi Komata and Barna, {Barbara P.} and Germano, {Isabelle M.} and Satoru Kyo and Satoshi Hirohata and Yasuko Kondo and Takao Kanzawa and Hideaki Ito and Satoshi Hirohata and Shoji Koga and Hideaki Sumiyoshi and Masahiro Takakura and Masaki Inoue",
year = "2002",
doi = "10.1089/104303402753812421",
language = "English",
volume = "13",
pages = "1015--1025",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells

AU - Komata, Tadashi

AU - Barna, Barbara P.

AU - Germano, Isabelle M.

AU - Kyo, Satoru

AU - Hirohata, Satoshi

AU - Kondo, Yasuko

AU - Kanzawa, Takao

AU - Ito, Hideaki

AU - Hirohata, Satoshi

AU - Koga, Shoji

AU - Sumiyoshi, Hideaki

AU - Takakura, Masahiro

AU - Inoue, Masaki

PY - 2002

Y1 - 2002

N2 - Telomerase is a distinctive candidate for targeted gene therapy of malignant gliomas, because the vast majority of malignant gliomas express telomerase activity while normal brain tissues do not. Recently, we developed a telomerase-specific expression system of caspase-8 gene using the promoter of the human telomerase reverse transcriptase (hTERT) gene. However, the transcriptional activity of hTERT-181 promoter (a 181-base pair [bp] region upstream of the transcription start site) was relatively lower in malignant glioma cells than in other tumors such as prostate cancer cells. To establish the hTERT/caspase-8 construct as a novel therapy for malignant gliomas, we need to increase the transcriptional activity of the hTERT promoter in malignant glioma cells. In the present study, we demonstrate that the transcriptional activity of hTERT-378 promoter (a 378-bp region) was 2- to 40-fold higher in hTERT-positive malignant glioma cells (A172, GB-1, T98G, U87-MG, U251-MG, and U373-MG) than that of hTERT-181. We further demonstrate that by using the hTERT-378/caspase-8 construct, apoptosis was restricted to malignant glioma cells, and was not seen in astrocytes or fibroblasts lacking hTERT. Moreover, the growth of subcutaneously established U373-MG tumors in mice was significantly inhibited by seven daily intratumoral injections of hTERT-378/caspase-8 construct and its inhibitory effect persisted during 3 additional weeks without additional treatment. These results suggest that the telomerase-specific expression of caspase-8 under hTERT-378 promoter is a novel targeting approach for the treatment of telomerase-positive malignant gliomas.

AB - Telomerase is a distinctive candidate for targeted gene therapy of malignant gliomas, because the vast majority of malignant gliomas express telomerase activity while normal brain tissues do not. Recently, we developed a telomerase-specific expression system of caspase-8 gene using the promoter of the human telomerase reverse transcriptase (hTERT) gene. However, the transcriptional activity of hTERT-181 promoter (a 181-base pair [bp] region upstream of the transcription start site) was relatively lower in malignant glioma cells than in other tumors such as prostate cancer cells. To establish the hTERT/caspase-8 construct as a novel therapy for malignant gliomas, we need to increase the transcriptional activity of the hTERT promoter in malignant glioma cells. In the present study, we demonstrate that the transcriptional activity of hTERT-378 promoter (a 378-bp region) was 2- to 40-fold higher in hTERT-positive malignant glioma cells (A172, GB-1, T98G, U87-MG, U251-MG, and U373-MG) than that of hTERT-181. We further demonstrate that by using the hTERT-378/caspase-8 construct, apoptosis was restricted to malignant glioma cells, and was not seen in astrocytes or fibroblasts lacking hTERT. Moreover, the growth of subcutaneously established U373-MG tumors in mice was significantly inhibited by seven daily intratumoral injections of hTERT-378/caspase-8 construct and its inhibitory effect persisted during 3 additional weeks without additional treatment. These results suggest that the telomerase-specific expression of caspase-8 under hTERT-378 promoter is a novel targeting approach for the treatment of telomerase-positive malignant gliomas.

UR - http://www.scopus.com/inward/record.url?scp=0036288826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036288826&partnerID=8YFLogxK

U2 - 10.1089/104303402753812421

DO - 10.1089/104303402753812421

M3 - Article

VL - 13

SP - 1015

EP - 1025

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 9

ER -